YMAB

Y-mAbs Therapeutics, Inc.

11.71 USD
+0.11 (+0.95%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Y-mAbs Therapeutics, Inc. stock is down -22.6% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 May’s closed higher than April. 100% of analysts rate it a buy.

About Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer in the United States. The company is developing DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor. GD2-GD3 vaccine that is in Phase II clinical trial for the. treatment of Stage 4 high-risk neuroblastoma.